Summary
Michael Mysinger is a Principal Scientist who blends machine learning, chemistry, and drug discovery, based in the San Francisco Bay Area with about a decade of experience. At Atomwise since 2016, he builds quantitative binding affinity models and rigorously audits data and predictions to root out bias and continually improve methods and metrics. Previously at SeaChange Pharmaceuticals, he led SEAware, a prediction engine for drug mechanism and toxicity, and helped design and launch the company's chemoinformatics storefront. His background spans a PhD from UCSF and earlier roles at Arqule and ConfometRx, with deep expertise in docking, QSAR, liver metabolism modeling, and rapid evaluation of predictive performance. Based in the SF Bay Area, he enjoys solving hard computational problems, mentoring teams, and turning complex requirements into robust, production-grade models.
11 years of coding experience
9 years of employment as a software developer
Johns Hopkins University
Ph.D., Drug Development Sciences, Ph.D., Drug Development Sciences at University of California, San Francisco
M.S., Computer Science, M.S., Computer Science at Stanford University